Article
"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses.
Current vascular pharmacology - 1 Sept 2011
Mikhailidis Dimitri P, Elisaf Moses, Rizzo Manfredi, Berneis Kaspar, Griffin Bruce, Zambon Alberto, Athyros Vasilios, de Graaf Jacqueline, März Winfried, Parhofer Klaus G, Rini Giovam Battista, Spinas Giatgen A, Tomkin Gerald H, Tselepis Alexandros D, Wierzbicki Anthony S, Winkler Karl, Florentin Matilda, Liberopoulos Evangelos
Abstract excerpt
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density liproproteins (LDL) subclasses. We sub-divided our statement in 2 sections. section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drug and lifestyle modifications....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.